SOX2 expression in the developing, adult, as well as, diseased prostate

X. Yu, J. M. Cates, C. Morrissey, C. You, M. M. Grabowska, J. Zhang, D. J. Degraff, D. W. Strand, O. E. Franco, O. Lin-Tsai, S. W. Hayward, R. J. Matusik

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background:SOX2 is a member of SOX (SRY-related high mobility group box) family of transcription factors.Methods:In this study, we examined the expression of SOX2 in murine and human prostatic specimens by immunohistochemistry.Results:We found that SOX2 was expressed in murine prostates during budding morphogenesis and in neuroendocrine (NE) prostate cancer (PCa) murine models. Expression of SOX2 was also examined in human prostatic tissue. We found that SOX2 was expressed in 26 of the 30 BPH specimens. In these BPH samples, expression of SOX2 was limited to basal epithelial cells. In contrast, 24 of the 25 primary PCa specimens were negative for SOX2. The only positive primary PCa was the prostatic NE tumor, which also showed co-expression of synaptophysin. Additionally, the expression of SOX2 was detected in all prostatic NE tumor xenograft lines. Furthermore, we have examined the expression of SOX2 on a set of tissue microarrays consisting of metastatic PCa tissues. Expression of SOX2 was detected in at least one metastatic site in 15 of the 24 patients with metastatic castration-resistant PCa; and the expression of SOX2 was correlated with synaptophysin.Conclusions:SOX2 was expressed in developing prostates, basal cells of BPH, as well as prostatic NE tumors.

Original languageEnglish (US)
Pages (from-to)301-309
Number of pages9
JournalProstate Cancer and Prostatic Diseases
Volume17
Issue number4
DOIs
StatePublished - Dec 13 2014

Fingerprint

Prostate
Prostatic Neoplasms
Neuroendocrine Tumors
Synaptophysin
Castration
Morphogenesis
Heterografts
Transcription Factors
Epithelial Cells
Immunohistochemistry

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Yu, X., Cates, J. M., Morrissey, C., You, C., Grabowska, M. M., Zhang, J., ... Matusik, R. J. (2014). SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer and Prostatic Diseases, 17(4), 301-309. https://doi.org/10.1038/pcan.2014.29

SOX2 expression in the developing, adult, as well as, diseased prostate. / Yu, X.; Cates, J. M.; Morrissey, C.; You, C.; Grabowska, M. M.; Zhang, J.; Degraff, D. J.; Strand, D. W.; Franco, O. E.; Lin-Tsai, O.; Hayward, S. W.; Matusik, R. J.

In: Prostate Cancer and Prostatic Diseases, Vol. 17, No. 4, 13.12.2014, p. 301-309.

Research output: Contribution to journalArticle

Yu, X, Cates, JM, Morrissey, C, You, C, Grabowska, MM, Zhang, J, Degraff, DJ, Strand, DW, Franco, OE, Lin-Tsai, O, Hayward, SW & Matusik, RJ 2014, 'SOX2 expression in the developing, adult, as well as, diseased prostate', Prostate Cancer and Prostatic Diseases, vol. 17, no. 4, pp. 301-309. https://doi.org/10.1038/pcan.2014.29
Yu, X. ; Cates, J. M. ; Morrissey, C. ; You, C. ; Grabowska, M. M. ; Zhang, J. ; Degraff, D. J. ; Strand, D. W. ; Franco, O. E. ; Lin-Tsai, O. ; Hayward, S. W. ; Matusik, R. J. / SOX2 expression in the developing, adult, as well as, diseased prostate. In: Prostate Cancer and Prostatic Diseases. 2014 ; Vol. 17, No. 4. pp. 301-309.
@article{16c81fce377d4779bd69f539ae7bcddb,
title = "SOX2 expression in the developing, adult, as well as, diseased prostate",
abstract = "Background:SOX2 is a member of SOX (SRY-related high mobility group box) family of transcription factors.Methods:In this study, we examined the expression of SOX2 in murine and human prostatic specimens by immunohistochemistry.Results:We found that SOX2 was expressed in murine prostates during budding morphogenesis and in neuroendocrine (NE) prostate cancer (PCa) murine models. Expression of SOX2 was also examined in human prostatic tissue. We found that SOX2 was expressed in 26 of the 30 BPH specimens. In these BPH samples, expression of SOX2 was limited to basal epithelial cells. In contrast, 24 of the 25 primary PCa specimens were negative for SOX2. The only positive primary PCa was the prostatic NE tumor, which also showed co-expression of synaptophysin. Additionally, the expression of SOX2 was detected in all prostatic NE tumor xenograft lines. Furthermore, we have examined the expression of SOX2 on a set of tissue microarrays consisting of metastatic PCa tissues. Expression of SOX2 was detected in at least one metastatic site in 15 of the 24 patients with metastatic castration-resistant PCa; and the expression of SOX2 was correlated with synaptophysin.Conclusions:SOX2 was expressed in developing prostates, basal cells of BPH, as well as prostatic NE tumors.",
author = "X. Yu and Cates, {J. M.} and C. Morrissey and C. You and Grabowska, {M. M.} and J. Zhang and Degraff, {D. J.} and Strand, {D. W.} and Franco, {O. E.} and O. Lin-Tsai and Hayward, {S. W.} and Matusik, {R. J.}",
year = "2014",
month = "12",
day = "13",
doi = "10.1038/pcan.2014.29",
language = "English (US)",
volume = "17",
pages = "301--309",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - SOX2 expression in the developing, adult, as well as, diseased prostate

AU - Yu, X.

AU - Cates, J. M.

AU - Morrissey, C.

AU - You, C.

AU - Grabowska, M. M.

AU - Zhang, J.

AU - Degraff, D. J.

AU - Strand, D. W.

AU - Franco, O. E.

AU - Lin-Tsai, O.

AU - Hayward, S. W.

AU - Matusik, R. J.

PY - 2014/12/13

Y1 - 2014/12/13

N2 - Background:SOX2 is a member of SOX (SRY-related high mobility group box) family of transcription factors.Methods:In this study, we examined the expression of SOX2 in murine and human prostatic specimens by immunohistochemistry.Results:We found that SOX2 was expressed in murine prostates during budding morphogenesis and in neuroendocrine (NE) prostate cancer (PCa) murine models. Expression of SOX2 was also examined in human prostatic tissue. We found that SOX2 was expressed in 26 of the 30 BPH specimens. In these BPH samples, expression of SOX2 was limited to basal epithelial cells. In contrast, 24 of the 25 primary PCa specimens were negative for SOX2. The only positive primary PCa was the prostatic NE tumor, which also showed co-expression of synaptophysin. Additionally, the expression of SOX2 was detected in all prostatic NE tumor xenograft lines. Furthermore, we have examined the expression of SOX2 on a set of tissue microarrays consisting of metastatic PCa tissues. Expression of SOX2 was detected in at least one metastatic site in 15 of the 24 patients with metastatic castration-resistant PCa; and the expression of SOX2 was correlated with synaptophysin.Conclusions:SOX2 was expressed in developing prostates, basal cells of BPH, as well as prostatic NE tumors.

AB - Background:SOX2 is a member of SOX (SRY-related high mobility group box) family of transcription factors.Methods:In this study, we examined the expression of SOX2 in murine and human prostatic specimens by immunohistochemistry.Results:We found that SOX2 was expressed in murine prostates during budding morphogenesis and in neuroendocrine (NE) prostate cancer (PCa) murine models. Expression of SOX2 was also examined in human prostatic tissue. We found that SOX2 was expressed in 26 of the 30 BPH specimens. In these BPH samples, expression of SOX2 was limited to basal epithelial cells. In contrast, 24 of the 25 primary PCa specimens were negative for SOX2. The only positive primary PCa was the prostatic NE tumor, which also showed co-expression of synaptophysin. Additionally, the expression of SOX2 was detected in all prostatic NE tumor xenograft lines. Furthermore, we have examined the expression of SOX2 on a set of tissue microarrays consisting of metastatic PCa tissues. Expression of SOX2 was detected in at least one metastatic site in 15 of the 24 patients with metastatic castration-resistant PCa; and the expression of SOX2 was correlated with synaptophysin.Conclusions:SOX2 was expressed in developing prostates, basal cells of BPH, as well as prostatic NE tumors.

UR - http://www.scopus.com/inward/record.url?scp=84909982232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909982232&partnerID=8YFLogxK

U2 - 10.1038/pcan.2014.29

DO - 10.1038/pcan.2014.29

M3 - Article

C2 - 25091041

AN - SCOPUS:84909982232

VL - 17

SP - 301

EP - 309

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -